Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

Market Cap	5.84B -27.1%
Revenue (ttm)	1.11B -14.4%
Net Income	-346.97M
EPS	-0.17
Shares Out	2.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,030,715
Open	2.960
Previous Close	2.920
Day's Range	2.810 - 2.960
52-Week Range	2.720 - 5.110
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company off...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,271
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300267

Financial Performance

In 2025, SHE:300267's revenue was 1.17 billion, an increase of 2.29% compared to the previous year's 1.14 billion. Losses were -379.82 million, 1.73% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error